Novo Nordisk, Inc. Company Profile

15:45 EDT 28th April 2015 | BioPortfolio

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.


News Articles [454 Associated News Articles listed on BioPortfolio]

Novo-Nordisk mit beeindruckender Performance!

Die Aktien des dänischen Pharmaunternehmens Novo-Nordisk haben seit Anfang Januar eine beeindruckende Performance gezeigt. Novo-Nordisk gehört zu den führenden Herstellern von Diabetes-Arzneimittel...

Novo Nordisk A/S: Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US

Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Dru...

Novo Nordisk A/S: Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity

Bagsværd, Denmark, 23 December 2014 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda® (liraglutide 3 mg), the f....

Novo Nordisk A/S: Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity

Bagsværd, Denmark, 22 January 2014 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinio...

BRIEF-Novo Nordisk has reduced the number of executives to six

COPENHAGEN, Nov 25 (Reuters) - Novo Nordisk A/S : ** Has reduced the number of executives from seven to six ** Executive vice president and chief of staffs Lise Kingo has decided to leave Novo Nordisk

Novo Nordisk, Transocean, Walgreen, Adamas and Novo Nordisk are big market movers

Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market: NYSE Novo Nordisk AS, up 95 cents to $43.67 U.S. regulators approved the pharmac...

Novo Nordisk A/S: Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 19 March 2015 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted: Financial year 2014 and 2015 The Company's audited Annual Report 20...

Novo Nordisk A/S - Trading in Novo Nordisk shares by board members, executives and associated persons on 30 October 2014

BAGSVAERD, Denmark, Oct. 31, 2014 (GLOBE NEWSWIRE) -- In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of ...

Drugs and Medications [33 Associated Drugs and Medications listed on BioPortfolio]

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

NOVOLIN N Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Physicians Total Care, Inc.]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

R HUMAN Novolin R Regular, Human Insulin Injection (recombinant DNA origin) USP 100 units/mL

PubMed Articles [265 Associated PubMed Articles listed on BioPortfolio]

Trigger Matters: An Ergonomy Analysis of Insulin Pens.

Background: Excessive force required to deliver a set dose of insulin as well as a localization of the push button and its upwards extension may result in significant difficulties to safely perform in...

RAMPART: a workflow management system for de novo genome assembly.

The de novo assembly of genomes from whole genome shotgun sequence data is a computationally intensive, multi-stage task and it is not known a priori which methods and parameter settings will produce ...

Maternal and fetal outcome in de novo preeclampsia in comparison to superimposed preeclampsia: a two-year observational study.

Aim: To assess the maternal and fetal outcome in women with de novo preeclampsia (PE) in comparison to superimposed PE. Study design: This was a prospective 2-year observational study carried out at M...

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.

Secondary AML (sAML) has a poor prognosis with conventional chemotherapy alone. Allogeneic hematopoietic cell transplantation (HCT) is beneficial for high-risk AML. Data comparing outcomes of transpla...

Pedigrees of infertile Chinese men with Y chromosome microdeletions derived from natural transmission and de novo mutation.

Y chromosome microdeletions can cause male infertility and are classified as natural transmission and de novo mutations. To examine the source of these deletions in Chinese men and to provide a theore...

Clinical Trials [220 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

The purpose of this study is to investigate and evaluate the effects of different interventions (1.continuous subcutaneous insulin infusion,2.multiple daily injections, 3.anti-hyperglycemi...

Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia

The aim of this study is to test the safety and efficacy of a new algorithm for intensive s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose concentra...

Comparison of 2 NovoFine® Needles on the Reflux of Insulin

This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and Nov...

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII) produced by two different manufacturers (N...

De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions

The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-m...

Companies [49 Associated Companies listed on BioPortfolio]

Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What make...

Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area ...

Novo Nordisk Inc.

More Information about "Novo Nordisk, Inc." on BioPortfolio

We have published hundreds of Novo Nordisk, Inc. news stories on BioPortfolio along with dozens of Novo Nordisk, Inc. Clinical Trials and PubMed Articles about Novo Nordisk, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novo Nordisk, Inc. Companies in our database. You can also find out about relevant Novo Nordisk, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record